Updated:
Getinge
Mattias Perjos leads Getinge, the publicly traded Gothenburg medtech group that books over SEK 30B in hospital-critical equipment sales annually.
Getinge
Getinge traces its roots to 1904 in the small Swedish town of Getinge, where it began manufacturing medical equipment. The company moved its headquarters to Gothenburg and, through a series of acquisitions over seven decades, evolved into a pure-play medtech group. Today it operates through three global business areas: Surgical Workflows, Acute Care Therapies, and Life Science. The common thread is hospital-critical infrastructure — operating tables, anesthesia machines, sterilizers, and bioreactors — equipment that unlocks procedural capacity for health systems. The group does not deploy capital as an institutional allocator would. Instead, it buys and integrates adjacent product lines. Past acquisitions include the 2014 purchase of Maquet, a cardiovascular and operating-room equipment specialist, and the 2020 bolt-on of Quadralene, a contamination-control chemistry manufacturer serving the biopharma sector (per the firm’s official communications). The footprint spans more than 40 countries, with manufacturing sites concentrated in Sweden, Germany, the United States, France, and China. A recurring source of live-systems revenue is surgical consumables and service contracts that attach to its installed base of sterile-processing capital equipment. Scale comes from hospital capex cycles, not limited-partner commitments. In 2023, Getinge reported net sales of SEK 31.8 billion and employed roughly 12,000 people (per the firm’s 2023 annual report). The company maintains a secondary listing on Nasdaq Stockholm and operates a venture unit, Getinge Ventures, which places minority stakes in early-stage medtech startups to monitor adjacent innovation but rarely consolidates them. There is no separate family-office entity or disclosed affiliated foundation. Structurally, Getinge is distinguished from a financial sponsor because it carries the full operational burden of design, regulatory clearance, manufacturing, and post-market surveillance for Class II and Class III medical devices. Its moat is not a funding cycle but a regulatory one — the multi-year lead time required to qualify a new sterile-processing line inside a hospital creates switching costs that pure-play private capital structures cannot replicate.
General information
Firm type
Asset Manager
Year founded
1904
AUM
Undisclosed
Location
Region
Europe
Country
Sweden
City
Gothenburg
Corporate office
Gothenburg, Sweden
Principals
Mattias Perjos
President & CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Getinge?
Investment decisions are not centralized in an investment committee like a family office. Capital allocation is driven by the CEO, Mattias Perjos, and the board of directors, with M&A and R&D budgets approved through the public-company governance process. The venture arm, Getinge Ventures, operates with a modest mandate and reports through the corporate development function.
Is Getinge structured as a family office or does it operate more like a venture firm?
Neither. Getinge is a publicly traded medical technology corporation listed on Nasdaq Stockholm. Its historical family-office roots — tracing back to the founding families in Getinge, Sweden — dissolved over a century of equity dilution, and no single family now controls the group. It functions as an industrial operating company that occasionally makes venture-stage investments through Getinge Ventures to monitor emerging technology.
Does Getinge participate in fund commitments or only direct deals?
Getinge makes direct corporate acquisitions and, through its venture unit, takes direct minority equity stakes in startups. It does not act as a limited partner in external private equity, venture capital, or hedge funds. All transactions are on its own balance sheet and are disclosed as corporate investments, not portfolio allocations.
What investment stages does Getinge typically target?
M&A targets are typically revenue-generating medtech and life science companies with established regulatory clearances. Getinge Ventures focuses on early-stage to Series B companies developing complementary devices or digital-health tools, typically with a product already in pilot inside a hospital or bioprocessing facility.
Which sectors does Getinge explicitly avoid?
Getinge avoids pure software plays, therapeutics, diagnostics without a hardware component, and consumer wellness. It does not invest in adjacent healthcare services like hospital staffing or revenue-cycle management. The group stays within regulated hospital-hardware and bio-processing equipment that aligns with its existing sales channels.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: